In its ninth year the Cancer Chemotherapy Annual series has been renamed, reformatted and expanded to include a section on biological response modifiers. It is, and will remain, the only medium for oncologists to keep pace with the many thousands of articles published in their field. The international board of some seventy contributors now also includes experts in biological therapeutics, who have evaluated their segment of the international medical literature. The editors, H.M. Pinedo and B.A. Chabner, have secured the assistance of D.L. Longo, who qualifies as the director of the Biological Response Modifiers Program of the National Cancer Institute in Frederick, MD, USA.
In its ninth year the Cancer Chemotherapy Annual series has been renamed, reformatted and expanded to include a section on biological response modifiers. It is, and will remain, the only medium for oncologists to keep pace with the many thousands of articles published in their field. The international board of some seventy contributors now also includes experts in biological therapeutics, who have evaluated their segment of the international medical literature. The editors, H.M. Pinedo and B.A. Chabner, have secured the assistance of D.L. Longo, who qualifies as the director of the Biological Response Modifiers Program of the National Cancer Institute in Frederick, MD, USA.
Reihe
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science & Technology
Zielgruppe
Für höhere Schule und Studium
Für Beruf und Forschung
Maße
Höhe: 250 mm
Breite: 190 mm
ISBN-13
978-0-444-90485-0 (9780444904850)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Klassifikation
Introduction (H.M. Pinedo and B.A. Chabner). I. DRUGS. 1. Antimetabolites (C.J. Allegra, J. Baram, B.A. Chabner, G.C. Yeh, K. Aiba and G.A. Curt). 2. Alkylating agents, nitrosoureas and alkyltriazenes (T.A. Connors). 3. The anthracyclines (C. Myers). 4. Bleomycins (Y. Muraoka and T. Takita). 5. Mitomycin C (J. den Hartigh, J. Verweij and H.M. Pinedo). 6. Vinca alkaloids (R.A. Bender). 7. Podophyllotoxin derivatives VP-16 and VM-26 (M. D'Incalci and S. Garattini). 8. Cisplatin and new platinum analogs (L.A. Zwelling). 9. Multidrug resistance (R.L. Fine and B.A. Chabner). 10. New anticancer agents (G.R. Weiss, C.L. Arteaga, T.D. Brown, J.B. Craig, G.S. Harman, J.M. Koeller, J.G. Kuhn and D.D. Von Hoff). 11. Steroid and peptide hormones and growth factors (A. Howell and A.E. Wakeling). II. TUMORS. 12. Leukemia and myelomatosis (D. Catovsky). 13. Lymphomas (D.L. Longo and V.T. DeVita). 14. Therapy of acquired immunodeficiency syndrome (R. Yarchoan, H. Masur and S. Broder). 15. Head and neck cancer (S.G. Taylor IV). 16. Lung cancer (H.H. Hansen and M. Rorth). 17. Upper gastrointestinal tumors (M. Ogawa and T. Taguchi). 18. Cancers of the large bowel and hepatobiliary system (J.A. Treat, J.D. Ahlgren and P.V. Woolley). 19. Endocrine tumors (J.J.M. van der Hoeven and P.S. Schein). 20. Genitourinary cancer (R.F. Ozols and A. Yagoda). 21. Gynecologic malignancies (R.C. Young). 22. Breast cancer (C.L. Loprinzi and P.P. Carbone). 23. Melanoma (Ph. Rumke). 24. Soft tissue and bone sarcomas (A. Santoro and G. Bonadonna). 25. Brain tumors (M.G. Malkin and W.R. Shapiro). 26. Pediatric tumors (D. Olive, E. Benz-Lemoine and P. Bey). 27. Supportive care (M. Markman). III. BIOLOGICAL RESPONSE MODIFIERS. 28. Monoclonal antibodies and immunoconjugates for cancer treatment (R.W. Baldwin and V.S. Byers). 29. Lymphokines and cytokines (J. Wagstaff and C.J. Melief). 30. Biological response modifiers: preclinical and clinical results (J.E. Talmadge and J. Clark). 31. Adoptive cellular therapy (W.J. Urba and D.L. Longo). 32. Strategies for immunological monitoring (W.J. Urba, A.E. Maluish and D.L. Longo). 33. Growth and differentiation control (G.E. Francis and C. Pinsky). List of abreviations of drugs. List of abbreviations of chemotherapeutic combinations. List of NSC numbers. Subject index (prepared by H. Kettner).
